Novel drug delivery systems for inflammatory bowel disease

作     者：Farah Yasmin Hala Najeeb Shehryar Shaikh Muhammad Hasanain Unaiza Naeem Abdul Moeed Thoyaja Koritala Syedadeel Hasan Salim Surani 

作者机构：Department of MedicineDow University of Health ScienceKarachi 74200Pakistan Department of MedicineDow OJha University HospitalKarachi 74200Pakistan Department of MedicineMayo Clinic Health SystemMankatoMN 56001United States Department of MedicineUniversity of LouisvilleLouisvilleKY 40292United States Department of MedicineTexas A&M UniversityCollege StationTX 77843United States Department of AnesthesiologyMayo ClinicRochesterMN 55901United States 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2022年第28卷第18期

页      面：1922-1933页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Inflammation Inflammatory bowel diseases Colitis Ulcerative Crohn’s disease Drug delivery systems Drug carrier 

摘      要：Inflammatory bowel disease(IBD)is a chronic illness characterized by relapsing inflammation of the *** disorder is stratified according to the severity and is marked by its two main phenotypical representations:Ulcerative colitis and Crohn’s *** of the disease is ambiguous and is expected to have interactivity between genetic disposition,environmental factors such as bacterial agents,and dysregulated immune *** for IBD aims to reduce symptom extent and severity and halt disease *** mainstay drugs have been 5-aminosalicylates(5-ASAs),corticosteroids,and immunosuppressive ***,oral and rectal routes are the conventional methods of drug delivery,and among all,oral administration is most widely ***,problems of systematic drug reactions and low specificity in delivering drugs to the inflamed sites have emerged with these regular routes of *** drug delivery systems have been introduced to overcome several therapeutic obstacles and for localized drug delivery to target ***-coated microneedle pills,various nano-drug delivery techniques,prodrug systems,lipid-based vesicular systems,hybrid drug delivery systems,and biologic drug delivery systems constitute some of these novel *** are painless,they dislodge their content at the affected site,and their release can be *** bacteria such as genetically engineered Lactococcus Lactis and eukaryotic cells,including GM immune cells and red blood cells as nanoparticle carriers,can be plausible delivery methods when evaluating biologic ***-particle drug delivery systems consisting of various techniques are also employed as nanoparticles can penetrate through inflamed regions and adhere to the thick mucus of the diseased *** systems such as 5-ASAs formulations or their derivatives are effective in reducing colonic *** can be modified with both hydrophilic and lipophilic p